163 related articles for article (PubMed ID: 20377136)
1. The CYP1A1 Ile462Val polymorphism and platinum resistance of epithelial ovarian neoplasms.
Heubner M; Wimberger P; Riemann K; Kasimir-Bauer S; Otterbach F; Kimmig R; Siffert W
Oncol Res; 2010; 18(7):343-7. PubMed ID: 20377136
[TBL] [Abstract][Full Text] [Related]
2. ERCC1, XRCC1, and GSTP1 Polymorphisms and Treatment Outcomes of Advanced Epithelial Ovarian Cancer Patients Treated with Platinum-based Chemotherapy.
Liblab S; Vusuratana A; Areepium N
Asian Pac J Cancer Prev; 2020 Jul; 21(7):1925-1929. PubMed ID: 32711417
[TBL] [Abstract][Full Text] [Related]
3. CYP1A1 gene polymorphism and risk of epithelial ovarian neoplasm.
Aktas D; Guney I; Alikasifoglu M; Yüce K; Tuncbilek E; Ayhan A
Gynecol Oncol; 2002 Aug; 86(2):124-8. PubMed ID: 12144816
[TBL] [Abstract][Full Text] [Related]
4. Claudin-4: a potential therapeutic target in chemotherapy-resistant ovarian cancer.
Yoshida H; Sumi T; Zhi X; Yasui T; Honda K; Ishiko O
Anticancer Res; 2011 Apr; 31(4):1271-7. PubMed ID: 21508375
[TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial growth factor (VEGF) polymorphism and increased risk of epithelial ovarian cancer.
Rinck-Junior JA; Oliveira C; Lourenço GJ; Sagarra RA; Derchain SF; Segalla JG; Lima CS
J Cancer Res Clin Oncol; 2015 Jan; 141(1):69-73. PubMed ID: 25092217
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab combined with platinum-taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial).
Komiyama S; Kato K; Inokuchi Y; Takano H; Matsumoto T; Hongo A; Asai-Sato M; Arakawa A; Kamiura S; Tabata T; Takeshima N; Sugiyama T
Int J Clin Oncol; 2019 Jan; 24(1):103-114. PubMed ID: 30030657
[TBL] [Abstract][Full Text] [Related]
7. Prediction value of XRCC 1 gene polymorphism on the survival of ovarian cancer treated by adjuvant chemotherapy.
Miao J; Zhang X; Tang QL; Wang XY; Kai L
Asian Pac J Cancer Prev; 2012; 13(10):5007-10. PubMed ID: 23244100
[TBL] [Abstract][Full Text] [Related]
8. The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer.
Steffensen KD; Waldstrøm M; Jakobsen A
Int J Gynecol Cancer; 2009 Jul; 19(5):820-5. PubMed ID: 19574766
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant platinum-based chemotherapy in patients with epithelial ovarian cancer: prognostic factors and final outcome.
Grivas A; Lianos E; Internos I; Papaxoinis G; Tselepatiotis E; Ziras N; Athanasiou AE
J BUON; 2010; 15(4):647-51. PubMed ID: 21229624
[TBL] [Abstract][Full Text] [Related]
10. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
Bamias A; Bamia C; Zagouri F; Kostouros E; Kakoyianni K; Rodolakis A; Vlahos G; Haidopoulos D; Thomakos N; Antsaklis A; Dimopoulos MA
Oncology; 2013; 84(3):158-65. PubMed ID: 23296063
[TBL] [Abstract][Full Text] [Related]
11. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study.
Bagnoli M; Canevari S; Califano D; Losito S; Maio MD; Raspagliesi F; Carcangiu ML; Toffoli G; Cecchin E; Sorio R; Canzonieri V; Russo D; Scognamiglio G; Chiappetta G; Baldassarre G; Lorusso D; Scambia G; Zannoni GF; Savarese A; Carosi M; Scollo P; Breda E; Murgia V; Perrone F; Pignata S; De Cecco L; Mezzanzanica D;
Lancet Oncol; 2016 Aug; 17(8):1137-1146. PubMed ID: 27402147
[TBL] [Abstract][Full Text] [Related]
12. Second-line Intraperitoneal Platinum-based Therapy Leads to an Increase in Second-line Progression-free Survival for Epithelial Ovarian Cancer.
Boisen MM; Lesnock JL; Richard SD; Beriwal S; Kelley JL; Zorn KK; Edwards RP
Int J Gynecol Cancer; 2016 May; 26(4):626-31. PubMed ID: 27051048
[TBL] [Abstract][Full Text] [Related]
13. Kallikrein-related peptidase 10 (KLK10) expression and single nucleotide polymorphisms in ovarian cancer survival.
Batra J; Tan OL; O'Mara T; Zammit R; Nagle CM; Clements JA; Kedda MA; Spurdle AB
Int J Gynecol Cancer; 2010 May; 20(4):529-36. PubMed ID: 20686372
[TBL] [Abstract][Full Text] [Related]
14. Impact of platinum on the whole mitochondrial genome of ovarian carcinomas both in vivo and in vitro.
Shi H; Pan L; Song T
Int J Gynecol Cancer; 2009 Apr; 19(3):423-30. PubMed ID: 19407571
[TBL] [Abstract][Full Text] [Related]
15. The AA genotype of a L1C G842A polymorphism is associated with an increased risk for ovarian cancer.
Heubner M; Wimberger P; Kasimir-Bauer S; Otterbach F; Kimmig R; Siffert W
Anticancer Res; 2009 Aug; 29(8):3449-52. PubMed ID: 19661372
[TBL] [Abstract][Full Text] [Related]
16. The androgen receptor cytosine-adenine-guanine repeat length contributes to the development of epithelial ovarian cancer.
Meng X; Lu P; Chu Z; Fan Q
Oncotarget; 2016 Jan; 7(2):2105-12. PubMed ID: 26556855
[TBL] [Abstract][Full Text] [Related]
17. Periostin in tumor microenvironment is associated with poor prognosis and platinum resistance in epithelial ovarian carcinoma.
Sung PL; Jan YH; Lin SC; Huang CC; Lin H; Wen KC; Chao KC; Lai CR; Wang PH; Chuang CM; Wu HH; Twu NF; Yen MS; Hsiao M; Huang CY
Oncotarget; 2016 Jan; 7(4):4036-47. PubMed ID: 26716408
[TBL] [Abstract][Full Text] [Related]
18. Clinical relationships between the rs2212020 and rs189897 polymorphisms of the
Liu J; Liu T; Liang L; He J; Zhang M; Ge Y; Liao S; Zhou Y; Zhang K
J Genet; 2019 Mar; 98():. PubMed ID: 30945681
[TBL] [Abstract][Full Text] [Related]
19. Role of neoadjuvant chemotherapy in the management of advanced ovarian cancer.
Zhao D; Wu LY; Wang XB; Li XG
Asian Pac J Cancer Prev; 2015; 16(6):2369-73. PubMed ID: 25824766
[TBL] [Abstract][Full Text] [Related]
20. Low drug resistance to both platinum and taxane chemotherapy on an in vitro drug resistance assay predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer.
Matsuo K; Bond VK; Eno ML; Im DD; Rosenshein NB
Int J Cancer; 2009 Dec; 125(11):2721-7. PubMed ID: 19530239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
